- Charles Scoggin, M.D.
Chief Executive Officer - Gary Rosenthal, Ph.D
Executive Vice President Research - Janice Troha
VP Product Development and Regulatory Affairs - Tom Sokolowski
CFO and VP Finance
Charles Scoggin, M.D.
Chief Executive Officer
Dr. Charles Scoggin has been Chief Executive Officer of N30 Pharmaceuticals since its founding in 2007.
Prior to entering the private sector, Dr. Scoggin was Professor of Medicine (with tenure) at the University of Colorado. Since that time, Dr. Scoggin has served as CEO of private and public biomedical companies.
Dr. Scoggin trained in internal medicine at Duke University and pulmonary and critical care medicine at the University of Colorado, and was a Senior Scientist at the Eleanor Roosevelt Institute.
During his academic career, Dr. Scoggin received numerous awards and recognitions. He was Teaching and Research Scholar of the American College of Physicians, a Fellow of the American College of Physicians, Research Scholar of the American Lung Association, and Fellow of the American College of Chest Physicians.
Dr. Scoggin has authored over 100 scientific articles, book chapters, and abstracts. These articles have been published in peer review journals, including: The New England Journal of Medicine, Journal of the American Medical Association, Proceedings of the National Academy of Sciences, American Journal of Human Genetics, Journal of Molecular and Somatic Cell Genetics, Chest, and the American Journal of Respiratory and Critical Care Medicine.
Gary Rosenthal, Ph.D
Executive Vice President Research
Dr. Gary Rosenthal has directed research and translational development efforts at N30 Pharmaceuticals since June 2007.
Prior to that, Dr. Rosenthal was VP of R & D at RxKinetix, Inc., Nobel Molecules, and headed pharmacology and toxicology at Somatogen, Inc. Dr. Rosenthal served as co-founder of Vasogenix Pharmaceuticals, Inc. and Nobel Molecules, LLC and served on the Board of Directors of the American Board of Toxicology and Vasogenix Pharmaceuticals, Inc.
Prior to his 18 years in industry, Dr. Rosenthal served as post doctoral research fellow, Project Officer, and tenured scientist in the Systems Toxicity Branch, National Institute of Environmental Health Sciences and the National Toxicology Program. Dr. Rosenthal received a M.S and Ph.D. from New York University’s Institute of Environmental Medicine and a Bachelors of Science degree in biology and philosophy from Boston College.
Janice Troha
VP Product Development and Regulatory Affairs
Ms. Janice Troha has served as the VP of Product Development and Regulatory Affairs for N30 Pharmaceuticals since October 2008.
Ms. Troha is the former Vice President of Clinical Development and Regulatory Affairs, and Site Head at Endo Pharmaceuticals, Colorado. She was a member of the Board of Directors and served as the Vice President of Clinical Development and Regulatory Affairs at RxKinetix, Inc., prior to the company’s acquisition by Endo Pharmaceuticals.
Ms. Troha has more than 25 years experience in clinical development and regulatory affairs, and has held a number of different leadership positions within the Pharmaceutical Industry, including Associate Director of Clinical Research and subsequently of International Medical Operations at Boehringer Ingelheim Pharmaceuticals, Inc., followed by Vice President of Development at Cortech, Inc.
During her tenure in the industry, Ms. Troha has created development strategies, and directed the clinical development of investigational new drugs across a broad range of therapeutic areas including cardiovascular, respiratory, traumatic injury, infectious diseases, and oncology. Prior to joining the industry, Ms Troha specialized in critical care nursing and clinical research.
Tom Sokolowski
Chief Financial Officer and VP of Finance
Mr. Tom Sokolowski has served as Chief Financial Officer for N30 Pharmaceuticals since May 2008.
Prior to joining N30 Pharma, Mr. Sokolowski was the Controller for eight years at Array BioPharma developing experience in treasury and cash management, SEC reporting and Sarbanes-Oxley compliance.
Mr. Sokolowski has over twenty-five years of progressive accounting and finance experience with numerous startup companies including previous employment as an expatriate Controller for a UK subsidiary and four years working as an auditor with Coopers & Lybrand, LLP.
Mr. Sokolowski holds a BS in Accounting from Northern Illinois University and is a CPA and a Certified Financial Planner.